Zentalis Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98943L1070
USD
2.55
0.02 (0.79%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Dynavax Technologies Corp.
Zentalis Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
Prothena Corp. Plc
Alvotech
Beam Therapeutics, Inc.
Arcellx, Inc.
Recursion Pharmaceuticals, Inc.
Nuvalent, Inc.
Ventyx Biosciences, Inc.
Rocket Pharmaceuticals, Inc.

Why is Zentalis Pharmaceuticals, Inc. ?

1
  • OPERATING CASH FLOW(Y) Highest at USD -134.01 MM
  • OPERATING PROFIT(Q) Highest at USD -33.57 MM
  • RAW MATERIAL COST(Y) Fallen by 0% (YoY)
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 24.75%, its profits have risen by 23.8%
3
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -1.7% over the previous quarter and currently hold 5.44% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Market Beating Performance
  • The stock has generated a return of 24.75% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Zentalis Pharmaceuticals, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zentalis Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Zentalis Pharmaceuticals, Inc.
28.79%
-0.77
99.66%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
94.55%
EBIT Growth (5y)
-18.15%
EBIT to Interest (avg)
-188.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.13
Sales to Capital Employed (avg)
0.11
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.77
EV to EBIT
0.53
EV to EBITDA
0.54
EV to Capital Employed
3.37
EV to Sales
-3.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
633.80%
ROE (Latest)
-54.03%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -134.01 MM

OPERATING PROFIT(Q)

Highest at USD -33.57 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

PRE-TAX PROFIT(Q)

Highest at USD -26.69 MM

NET PROFIT(Q)

Highest at USD -26.69 MM

EPS(Q)

Highest at USD -0.37

-2What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 584.13 MM

DEBT-EQUITY RATIO (HY)

Highest at -95 %

Here's what is working for Zentalis Pharmaceuticals, Inc.

Operating Cash Flow
Highest at USD -134.01 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit
Highest at USD -33.57 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -26.69 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -26.69 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.37
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zentalis Pharmaceuticals, Inc.

Cash and Eqv
Lowest at USD 584.13 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at -95 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio